The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acquired | Acquired

Total Raised


About Autonomic Technologies

Autonomic Technologies (ATI) is a medical device company headquartered in the San Francisco Bay Area with offices in Germany and Switzerland, focused on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. The company's initial product, the Pulsante microstimulator, is CE marked in Europe for the treatment of cluster headache. The device is also under an IDE study in the US for the treatment of chronic cluster headache.

Autonomic Technologies Headquarter Location

3698 Haven Avenue Suite C

Redwood City, California, 94063,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Autonomic Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Autonomic Technologies is included in 2 Expert Collections, including Medical Devices.


Medical Devices

7,913 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Autonomic Technologies Patents

Autonomic Technologies has filed 41 patents.

The 3 most popular patent topics include:

  • Bones of the head and neck
  • Neurophysiology
  • Neurotechnology
patents chart

Application Date

Grant Date


Related Topics




Neurological disorders, Bones of the head and neck, Neurophysiology, Neurotechnology, Implants (medicine)


Application Date


Grant Date



Related Topics

Neurological disorders, Bones of the head and neck, Neurophysiology, Neurotechnology, Implants (medicine)



Latest Autonomic Technologies News

Global Neurostimulation Devices Market Report 2022: Market is Expected to Record a Volume of $22.49 Billion in 2028 | The Brainy Insights

Mar 8, 2022

| The Brainy Insights The Neurostimulation Devices Market study is a perfect mix of qualitative and quantitative information and to get better understanding on how stats relates to growth, market sizing and share, the study is started with market overview and further detailed commentary is showcased on changing market dynamics that includes Influencing trends by regions, growth drivers, long term opportunities and short term challenges that industry players are facing. Furthermore, Market Factor Analysis gives insights on how various regulatory affairs, economic factors and policy action are factored in the past and future growth scenarios by various business segments and applications. The Competitive Landscape provides detailed company profiling of players and draws attention on development activities, SWOT, financial outlook and major business strategic action taken by players. Get Sample Report + All Related Graphs & Charts @ Industries and markets are ever-evolving; navigate these changes with ongoing research conducted by The Brainy Insights; Address the latest insights released on Global Neurostimulation Devices Market. Relevant features of the study that are being offered with major highlights from the report: 1) Can Market be broken down by different set of application and types? Additional segmentation / Market breakdown is possible subject to data availability, feasibility and depending upon timeline and toughness of survey. However a detailed requirement needs to be prepared before making any final confirmation. ** An additional country of your interest can be included at no added cost feasibility test would be conducted by Analyst team of THE BRAINY INSIGHTS based on the requirement shared and accordingly deliverable time will also be disclosed. 2) How Study Have Considered the Impact of Economic Slowdown of 2020? Analyst at The Brainy Insights have conducted special survey and have connected with opinion leaders and Industry experts from various region to minutely understand impact on growth as well as local reforms to fight the situation. A special chapter in the study presents Impact and Market factor Analysis on Global Neurostimulation Devices Market along with tables and graphs related to various country and segments showcasing impact on growth trends. 3) Which companies are profiled in current version of the report? Can list of players be customize based on regional geographies we are targeting Considering heat map analysis and based on market buzz or voice the profiled list of companies in the report are NeuroSigma, Inc., Boston Scientific Corporation, LivaNova PLC., Cochlear Ltd., Endostim Inc., Medtronic, Autonomic Technologies, AlevaNeurotherapeutics SA, Synapse Biomedical Inc., BioControl Medical, NeuroPaceInc, Allergan. Yes, further list of players can also be customized as per your requirement keeping in mind your areas of interest and adding local emerging players and leaders from targeted geography. ** List of companies covered may vary in the final report subject to Name Change / Merger & Acquisition Activity etc. based on the difficulty of survey since data availability needs to be confirmed by research team especially in case of privately held company. Up to 2 players can be added at no additional cost. To comprehend Global Neurostimulation Devices market dynamics in the global market, the worldwide Neurostimulation Devices market is analyzed across major geographical regions. The Brainy Insights Market Intelligence also provides customized specific regional and country-level reports, see below break-ups. Browse now for Full Report Index or a Sample Copy @ North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, LATAM, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Israel, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, BeNeLux, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Thailand, Singapore, and Australia. 2-Page company profiles for 10+ leading players is included with 3 years financial history to illustrate the recent performance of the market. Latest and updated discussion for 2019 major macro and micro elements influencing market and impacting the sector are also provided with a thought-provoking qualitative remarks on future opportunities and likely threats. The study is a mix of both statistically relevant quantitative data from the industry, coupled with insigThe Brainy Insightsul qualitative comment and analysis from Industry experts and consultants. Global Neurostimulation Devices Product Types In-Depth: Implantable Devices Parkinson’s Disease Others Market Sizing by Geographical Break-down: North America (Covered in Chapter 9), United States, Canada, Mexico, Europe (Covered in Chapter 10), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 11), China, Japan, South Korea, Australia, India, South America (Covered in Chapter 12), Brazil, Argentina, Columbia, Middle East and Africa (Covered in Chapter 13), UAE, Egypt & South Africa To ascertain a deeper view of Market Size, competitive landscape is provided i.e. Comparative Market Share Revenue Analysis (Million USD) by Players (2018-2019) & Segment Market Share (%) by Players (2018-2019) and further a qualitative analysis of all players is made to understand market concentration rate. Competitive Landscape & Analysis: Major players of Neurostimulation Devices Market are focusing highly on innovation in new technologies to improve production efficiency and re-arrange product lifecycle. Long-term growth opportunities for this sector are captured by ensuring ongoing process improvements of related players following NAICS standard by understanding their financial flexibility to invest in the optimal strategies. Company profile section of players such as NeuroSigma, Inc., Boston Scientific Corporation, LivaNova PLC., Cochlear Ltd., Endostim Inc., Medtronic, Autonomic Technologies, AlevaNeurotherapeutics SA, Synapse Biomedical Inc., BioControl Medical, NeuroPaceInc, Allergan includes vital information like legal name, website, headquarter, its market position, distribution and marketing channels, historical background and top 4 closest competitors by Market capitalization / turnover along with sales contact information. Each company / manufacturers revenue figures, growth rate, net profit and gross profit margin is provided in easy to understand tabular format for past 3 years and a separate section on market entropy covering recent development activities like mergers &acquisition, new product/service launch, funding activity etc. Get Latest Edition of Global Neurostimulation Devices Market Study at Revised offered Price In this study, the years considered to estimate the market size of Global Neurostimulation Devices are as follows: History Year: 2014-2019, Base Year: 2019, Forecast Year 2020 to 2025 Key Stakeholders / Target Audience Covered: In order to better analyze value chain/ supply chain of the Industry, a lot of attention given to backward & forward Integration Neurostimulation Devices Manufacturers Downstream Vendors Actual Numbers & In-Depth Analysis of Neurostimulation Devices Market Size Estimation, Business opportunities, Available in Full Report. Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific. Enquire for making customized Report @ About The Brainy Insights: The Brainy Insights is a market research company, aimed at providing actionable insights through data analytics to companies to improve their business acumen. We have a robust forecasting and estimation model to meet the clients’ objectives of high-quality output within a short span of time. We provide both customized (clients’ specific) and syndicate reports. Our repository of syndicate reports is diverse across all the categories and sub-categories across domains. Our customized solutions are tailored to meet the clients’ requirement whether they are looking to expand or planning to launch a new product in the global market. Contact Us

  • Where is Autonomic Technologies's headquarters?

    Autonomic Technologies's headquarters is located at 3698 Haven Avenue, Redwood City.

  • What is Autonomic Technologies's latest funding round?

    Autonomic Technologies's latest funding round is Acquired.

  • How much did Autonomic Technologies raise?

    Autonomic Technologies raised a total of $98.62M.

  • Who are the investors of Autonomic Technologies?

    Investors of Autonomic Technologies include Realeve, HBM Healthcare Investments, InterWest Partners, Kleiner Perkins Caufield & Byers, Aberdare Ventures and 7 more.

  • Who are Autonomic Technologies's competitors?

    Competitors of Autonomic Technologies include MedShape, Relievant Medsystems, Intercure, Cianna Medical, Inspire Medical Systems and 12 more.

You May Also Like


Apneon is an early stage medical device company developing devices for the treatment of sleep apnea.


Linguaflex is a medical device company with a patent pending technology to treat obstructive sleep apnea. LinguaFlex's LTR is implanted and designed to be comfortable, therefore addressing the lack of compliance as an issue in the successful treatment of OSA.


Neuromonics is an Australian company that has developed an FDA approved device for treatment of tinnitus over a six month process with 2 hours of use per day.


AllTranz aims to provide relief from chronic pain to patients outside the hospital setting.

Monterey Devices

Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.

Beta-O2 Technologies

Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the ßAir. The company's flagship product is called the ßAir Bio-artificial Pancreas. It is in development as a treatment and potential cure for type 1 diabetes (T1D). ßAir was first designed to address the main problems of the otherwise successful procedures in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and limited functionality of the transplanted islets over time due to an insufficient oxygen supply. The company's second pipeline product is the ßAir Bio-artificial Adrenal for the treatment of adrenocortical insufficiency and other stress-related disorders. This product is currently at the pre-clinical stage of development.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.